CDKN2B Regulates TGF β Signaling and Smooth Muscle Cell Investment of Hypoxic Neovessels

Circulation Research

Volumn 118, Issue 2, 2016, Pages 230-240

  Nanda, Vivek ^a   Downing, Kelly P ^a   Ye, Jianqin ^a   Xiao, Sophia ^a   Kojima, Yoko ^a   Spin, Joshua M ^a   Direnzo, Daniel ^a   Nead, Kevin T ^a   Connolly, Andrew J ^d   Dandona, Sonny ^b   Perisic, Ljubica ^c   Hedin, Ulf ^c   Maegdefessel, Lars ^d   Dalman, Jessie ^a   Guo, Liang ^d   Zhao, Xiaoqing ^d   Kolodgie, Frank D ^d   Virmani, Renu ^d   Davis, Harry R ^d   Leeper, Nicholas J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c KAROLINSKA INSTITUTE   (Sweden)

^d CVPATH INSTITUTE   (United States)

Author keywords

atherosclerosis; cyclin dependent kinase inhibitor p15; genetic variation; pathologic angiogenesis; peripheral artery disease; smooth muscle cells

Indexed keywords

CDKN2B PROTEIN, HUMAN; CDKN2B PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 2B; SMAD7 PROTEIN; SMAD7 PROTEIN, MOUSE; TGFB1 PROTEIN, HUMAN; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; ANIMAL; ATHEROSCLEROSIS; C57BL MOUSE; CAROTID ARTERY; CELL CULTURE; CELL HYPOXIA; CHROMOSOME 9; CORONARY BLOOD VESSEL; DEFICIENCY; DISEASE MODEL; ENZYMOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; HINDLIMB; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SMOOTH MUSCLE CELL; TIME FACTOR; VASCULAR SMOOTH MUSCLE; VASCULARIZATION;

ANIMALS; ATHEROSCLEROSIS; CAROTID ARTERIES; CELL HYPOXIA; CELLS, CULTURED; CHROMOSOMES, HUMAN, PAIR 9; CORONARY VESSELS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DISEASE MODELS, ANIMAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HINDLIMB; HUMANS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SKELETAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOTYPE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMAD7 PROTEIN; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84955243591     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.307906     Document Type: Article

References (45)

1. Krimpenfort P, Ijpenberg A, Song JY, van der Valk M, Nawijn M, Zevenhoven J, Berns A., p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 2007:448-943 946. doi: 10.1038/nature06084.
2. Pilbrow AP, Folkersen L, Pearson JF, et al.The chromosome 9p21.3 coronary heart disease risk allele is associated with altered gene expression in normal heart and vascular tissues. PLoS One 2012;7 e39574. doi: 10.1371/journal.pone.0039574.
3. Motterle A, Pu X, Wood H, Xiao Q, Gor S, Ng FL, Chan K, Cross F, Shohreh B, Poston RN, Tucker AT, Caulfield MJ, Ye S., Functional analyses of coronary artery disease associated variation on chromosome 9p21-in vascular smooth muscle cells. Hum Mol Genet 2012:21:4021-4029. doi: 10.1093/hmg/dds224.
4. Leeper NJ, Raiesdana A, Kojima Y, Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation. Arterioscler Thromb Vasc Biol 2013;33:e1-e10. doi: 10.1161/ATVBAHA.112.300399.
5. Kojima Y, Downing K, Kundu R, Miller C, Dewey F, Lancero H, Raaz U, Perisic L, Hedin U, Schadt E, Maegdefessel L, Quertermous T, Leeper NJ., Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis. J Clin Invest 2014;124:1083-1097. doi: 10.1172/JCI70391.
6. Helgadottir A, Thorleifsson G, Magnusson KP, The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008;40:217-224. doi: 10.1038/ng.72.
7. Murabito JM, White CC, Kavousi M, Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genome-wide association studies. Circ Cardiovasc Genet 2012;5:100-112. doi: 10.1161/CIRCGENETICS.111.961292.
8. Cluett C, McDermott MM, Guralnik J, Ferrucci L, Bandinelli S, Miljkovic I, Zmuda JM, Li R, Tranah G, Harris T, Rice N, Henley W, Frayling TM, Murray A, Melzer D., The 9p21 myocardial infarction risk allele increases risk of peripheral artery disease in older people. Circ Cardiovasc Genet 2009;2:347-353. doi: 10.1161/CIRCGENETICS.108.825935.
9. Downing KP, Nead KT, Kojima Y, Assimes T, Maegdefessel L, Quertermous T, Cooke JP, Leeper NJ., The combination of 9p21.3 genotype and biomarker profile improves a peripheral artery disease risk prediction model. Vasc Med 2014;19:3-8. doi: 10.1177/1358863X13514791.
10. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH., Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000;and 2010: a systematic review and analysis. Lancet 2013:382-1329 1340. doi: 10.1016/S0140-6736(13)61249-0.
11. Mahoney EM, Wang K, Cohen DJ, Hirsch AT, Alberts MJ, Eagle K, Mosse F, Jackson JD, Steg PG, Bhatt DL, REACH Registry Investigators One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes 2008;1;38-45. doi: 10.1161/CIRCOUTCOMES.108.775247.
12. Kullo IJ, Leeper NJ., The genetic basis of peripheral arterial disease: current knowledge, challenges, and future directions. Circ Res 2015-116 1551 1560. doi: 10.1161/CIRCRESAHA.116.303518.
13. Sluimer JC, Kolodgie FD, Bijnens AP, Maxfield K, Pacheco E, Kutys B, Duimel H, Frederik PM, van Hinsbergh VW, Virmani R, Daemen MJ., Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol 2009;53:1517-1527. doi: 10.1016/j.jacc.2008.12.056.
14. Perisic L, Hedin E, Razuvaev A, Lengquist M, Osterholm C, Folkersen L, Gillgren P, Paulsson-Berne G, Ponten F, Odeberg J, Hedin U., Profiling of atherosclerotic lesions by gene and tissue microarrays reveals PCSK6 as a novel protease in unstable carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2013;33:2432-2443. doi: 10.1161/ATVBAHA.113.301743.
15. Ahn GO, Seita J, Hong BJ, Kim YE, Bok S, Lee CJ, Kim KS, Lee JC, Leeper NJ, Cooke JP, Kim HJ, Kim IH, Weissman IL, Brown JM., Transcriptional activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells promotes angiogenesis through VEGF and S100A8. Proc Natl Acad Sci USA 2014;111:2698-2703. doi: 10.1073/pnas.1320243111.
16. Niiyama H, Huang NF, Rollins MD, Cooke JP., Murine model of hindlimb ischemia. J Vis Exp 2009;23:1035. doi: 10.3791/1035.
17. Leeper NJ, Tedesco MM, Kojima Y, Schultz GM, Kundu RK, Ashley EA, Tsao PS, Dalman RL, Quertermous T., Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol 2009-296 H1329 H1335. doi: 10.1152/ajpheart.01341.2008.
18. Leeper NJ, Raiesdana A, Kojima Y, Chun HJ, Azuma J, Maegdefessel L, Kundu RK, Quertermous T, Tsao PS, Spin JM., MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. J Cell Physiol 2011;226:1035-1043. doi: 10.1002/jcp.22422.
19. Tusher VG, Tibshirani R, Chu G., Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-5121. doi: 10.1073/pnas.091062498.
20. Huang da W, Sherman BT, Lempicki RA., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4 44:57. doi: 10.1038/nprot.2008.211.
21. Cunnington MS, Keavney B., Genetic mechanisms mediating atherosclerosis susceptibility at the chromosome 9p21 locus. Curr Atheroscler Rep 2011;13:193-201. doi: 10.1007/s11883-011-0178-z.
22. van Royen N, Hoefer I, Buschmann I, Heil M, Kostin S, Deindl E, Vogel S, Korff T, Augustin H, Bode C, Piek JJ, Schaper W., Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB J 2002;16:432-434. doi: 10.1096/fj.01-0563fje.
23. Bertolino P, Deckers M, Lebrin F, ten Dijke P., Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 2005;128:585S-590S. doi: 10.1378/chest.128.6-suppl.585S.
24. Goumans MJ, Liu Z, ten Dijke P., TGF-beta signaling in vascular biology and dysfunction. Cell Res 2009-19 116 127. doi: 10.1038/cr.2008.326.
25. Gaengel K, Genové G, Armulik A, Betsholtz C., Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 2009;29:630-638. doi: 10.1161/ATVBAHA.107.161521.
26. Pollman MJ, Naumovski L, Gibbons GH., Vascular cell apoptosis: cell type-specific modulation by transforming growth factor-beta1 in endothelial cells versus smooth muscle cells. Circulation 1999;99:2019-2026
27. Carmeliet P., Angiogenesis in health and disease. Nat Med 2003;9; 653-660. doi: 10.1038/nm0603-653.
28. Bobik A., Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol 2006-26 1712 1720. doi: 10.1161/01.ATV.0000225287.20034.2c.
29. Kobayashi K, Yokote K, Fujimoto M, Yamashita K, Sakamoto A, Kitahara M, Kawamura H, Maezawa Y, Asaumi S, Tokuhisa T, Mori S, Saito Y., Targeted disruption of TGF-beta-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury. Circ Res 2005;96;904-912. doi: 10.1161/01.RES.0000163980.55495.44.
30. Wang H, Song K, Krebs TL, Yang J, Danielpour D., Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55. Oncogene 2008;27:6791-6805. doi: 10.1038/onc.2008.291.
31. Kim-Kaneyama JR, Lei XF, Arita S, Miyauchi A, Miyazaki T, Miyazaki A., Hydrogen peroxide-inducible clone 5 (Hic-5) as a potential therapeutic target for vascular and other disorders. J Atheroscler Thromb 2012;19:601-607
32. Komorowsky C, Samarin J, Rehm M, Guidolin D, Goppelt-Struebe M., Hic-5 as a regulator of endothelial cell morphology and connective tissue growth factor gene expression. J Mol Med (Berl) 2010;88:623-631. doi: 10.1007/s00109-010-0608-3.
33. Avraamides C, Bromberg ME, Gaughan JP, Thomas SM, Tsygankov AY, Panetti TS., Hic-5 promotes endothelial cell migration to lysophosphatidic acid. Am J Physiol Heart Circ Physiol 2007;293:H193-H203. doi: 10.1152/ajpheart.00728.2006.
34. Wang X, Hu G, Betts C, Harmon EY, Keller RS, Van De Water L, Zhou J., Transforming growth factor-β1-induced transcript 1 protein, a novel marker for smooth muscle contractile phenotype, is regulated by serum response factor/myocardin protein. J Biol Chem 2011;286:41589-41599. doi: 10.1074/jbc.M111.250878.
35. Kim-Kaneyama JR, Wachi N, Sata M, Enomoto S, Fukabori K, Koh K, Shibanuma M, Nose K., Hic-5, an adaptor protein expressed in vascular smooth muscle cells, modulates the arterial response to injury in vivo. Biochem Biophys Res Commun 2008;376:682-687. doi: 10.1016/j.bbrc.2008.09.051.
36. Wang H, Song K, Sponseller TL, Danielpour D., Novel function of androgen receptor-associated protein 55/Hic-5 as a negative regulator of Smad3 signaling. J Biol Chem 2005;280:5154-5162. doi: 10.1074/jbc.M411575200.
37. Michel JB, Virmani R, Arbustini E, Pasterkamp G., Intraplaque haemorrhages as the trigger of plaque vulnerability. Eur Heart J 2011;32:1977-1985, 1985a, 1985b, 1985c. doi: 10.1093/eurheartj/ehr054.
38. Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Mohlke KL, Ibrahim JG, Thomas NE, Sharpless NE., INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One 2009;4 e5027. doi: 10.1371/journal.pone.0005027.
39. Svensson PA, Wahlstrand B, Olsson M, Froguel P, Falchi M, Bergman RN, McTernan PG, Hedner T, Carlsson LM, Jacobson P., CDKN2B expression and subcutaneous adipose tissue expandability: possible influence of the 9p21-atherosclerosis locus. Biochem Biophys Res Commun 2014, 446:1126-1131. doi: 10.1016/j.bbrc.2014.03.075.
40. Holdt LM, Beutner F, Scholz M, Gielen S, Gäbel G, Bergert H, Schuler G, Thiery J, Teupser D., ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler Thromb Vasc Biol 2010;30:620-627. doi: 10.1161/ATVBAHA.109.196832.
41. Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B., Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression. PLoS Genet 2010;6 e1000899. doi: 10.1371/journal.pgen.1000899.
42. Johnson AD, Hwang SJ, Voorman A, et al. Resequencing and clinical associations of the 9p21.3-region: a comprehensive investigation in the Framingham Heart Study. Circulation 2013 127 799 810. doi: 10.1161/CIRCULATIONAHA.112.111559.
43. Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberg AP, Cui H., Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 2008;451:202-206. doi: 10.1038/nature06468.
44. Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, Blow MJ, Cohen JC, Rubin EM, Pennacchio LA., Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 2010;464:409-412. doi: 10.1038/nature08801.
45. Loinard C, Basatemur G, Masters L, Baker L, Harrison J, Figg N, Vilar J, Sage AP, Mallat Z., Deletion of chromosome 9p21 noncoding cardiovascular risk interval in mice alters Smad2 signaling and promotes vascular aneurysm. Circ Cardiovasc Genet 2014;7;799-805. doi: 10.1161/CIRCGENETICS.114.000696.